Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Octapharma
Age
5–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who meet all of the following criteria are eligible for the study:
Male or female patients aged ≥5.5 years at the time of enrolment
VWD type 1 (baseline von Willebrand factor activity \[VWF:RCo\], \<30 IU/dL), 2A, 2B, 2M, or 3 according to medical history requiring substitution therapy with a VWF-containing product to control bleeding
Currently receiving frequent on-demand treatment with a VWF-containing product
In female patients of child-bearing potential using hormonal contraception, the medication class should remain unchanged for the duration of their study participation
Voluntarily given, fully informed written and signed consent obtained before collection of any patient data
You may not be if
Patients currently on prophylaxis for VWD (except for perioperative prophylaxis) as well as patients having received treatment once a month for menstrual bleeding, but not for any other bleeds
Patients whose VWD treatment is planned to be switched from on-demand to prophylactic treatment in the next 6 months
History, or current suspicion, of VWF or FVIII inhibitors
Medical history of a thromboembolic event within 6 months before enrolment
Severe liver or kidney diseases as described in the medical records
Female patients with an existing or suspected pregnancy or who are breast-feeding at the time of enrolment
Change in hormonal contraception within 6 months before enrolment
Cervical or uterine conditions causing abnormal uterine bleeding (including infection or dysplasia)
Other coagulation disorders or bleeding disorders due to anatomical reasons
Participation in an interventional clinical study during the 6-month of study period
Inability to complete the patient diary to reliably evaluate the type, frequency, and treatment of BEs during the 6-month study period
